Qiagen

Qiagen

Provider of molecular Sample to Insight solutions.

  • Edit

Financials

Estimates*

Get premium to view all results
Edit
Revenues, earnings & profits over time
USD2021202220232024202520262027
Revenues0000000000000000000000000000
% growth20 %(5 %)(8 %)1 %4 %6 %7 %
EBITDA0000000000000000000000000000
% EBITDA margin41 %46 %37 %24 %38 %38 %39 %
Profit0000000000000000000000000000
% profit margin23 %27 %17 %4 %21 %22 %23 %
EV0000000000000000000000000000
EV / revenue00.0x00.0x00.0x00.0x00.0x00.0x00.0x
EV / EBITDA00.0x00.0x00.0x00.0x00.0x00.0x00.0x
R&D budget0000000000000000000000000000
R&D % of revenue8 %8 %10 %10 %---

Source: Company filings or news article, Equity research estimates

More about Qiagen
Made with AI
Edit

QIAGEN is a global leader in providing molecular testing solutions that enable researchers and clinicians to unlock valuable insights from DNA, RNA, and proteins. Operating in the life sciences and diagnostics markets, QIAGEN serves a diverse range of clients including academic institutions, pharmaceutical companies, and clinical laboratories. The company offers a comprehensive portfolio of products, including sample technologies, assay technologies, and bioinformatics software, designed to streamline the workflow from sample collection to data interpretation.

QIAGEN's business model revolves around the sale of consumables, instruments, and software solutions. The company generates revenue through the direct sale of these products, as well as through service contracts and licensing agreements. By focusing on innovation and customer-centric solutions, QIAGEN aims to address the evolving needs of the molecular biology and diagnostics sectors.

Key products include the QIAseq UPXome RNA Library Kits, which maximize gene expression insights from minimal RNA amounts, and the QIAstat Dx Viral Vesicular Panel, which enhances research and surveillance efforts for viruses like monkeypox. Additionally, QIAGEN offers the QIAstat Dx Analyzer, a fully integrated and scalable digital PCR system that delivers precise results quickly and efficiently.

Keywords: molecular testing, DNA analysis, RNA analysis, protein analysis, life sciences, diagnostics, sample technologies, assay technologies, bioinformatics, QIAstat Dx.

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo
Investments analysisEdit
  • Edit
Protagen
ACQUISITION by Oncimmune Mar 2019
Genoox
ACQUISITION by Qiagen May 2025
STAT-Dx
ACQUISITION by Qiagen Feb 2018
CLC bio
ACQUISITION by Qiagen Oct 2013
PrimeraDx
ACQUISITION by Qiagen Jun 2014
N-of-One
ACQUISITION by Qiagen Jan 2019
BIOBASE
ACQUISITION by Qiagen May 2014
SABiosciences
ACQUISITION by Qiagen Dec 2009
Intelligent Bio-Systems
ACQUISITION by Qiagen Jun 2012
View 10 more